FDA PMA FDA Class 2 Approved 🇺🇸 United States

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

PMA: P030056 · Supplement: S004 · Decision Apr 9, 2009
Classifications
1
FEI Numbers
24
Registration Numbers
24

Basic Information

Device Name
Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Trade Name
ADVIA CENTAUR HCV READYPACK REAGENNTS/QUALITY CONTROL MATERIALS
PMA Number
P030056
Supplement Number
S004
Device Class
FDA Class 2
Product Code
MZO
Generic Name
Assay, enzyme linked immunosorbent, hepatitis c virus
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
April 9, 2009
Date Received
March 9, 2009
Supplement Type
Normal 180 Day Track No User Fee
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR ADDING ADVIA CENTAUR XP INSTRUMENT TO THE INTENDED USE OF THEAPPROVED DEVICE ADVIA CENTAUR HCV ASSAY. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ADVIA CENTAUR HCV ASSAY AND IS INDICATED FOR:ADVIA CENTAUR HCV ASSAY:THE ADVIA CENTAUR HCV ASSAY IS AN IN VITRO DIAGNOSTIC IMMUNOASSAY FOR THE QUALITATIVEDETERMINATION OF IMMUNOGLOBULIN G (IGG) ANTIBODIES TO HEPATITIS C VIRUS (HCV) IN HUMAN SERUM AND PLASMA (EDTA, LITHIUM OR SODIUM HEPARIN) USING THE ADVIA CENTAUR AND ADVIA CENTAUR XP SYSTEMS. THE ASSAY MAY BE USED IN CONJUNCTION WITH OTHER SEROLOGICAL AND CLINICAL INFORMATION TO AID IN THE DIAGNOSIS OF INDIVIDUALS WITH SYMPTOMS OF HEPATITIS AND IN INDIVIDUALS AT RISK FOR HEPATITIS C INFECTION.ADVIA CENTAUR HCV QUALITY CONTROLS:FOR IN VITRO DIAGNOSTIC USE IN MONITORING THE PERFORMANCE OF THE HCV ASSAY ON THEADVIA CENTAUR SYSTEMS. THE PERFORMANCE OF THE HCV QUALITY CONTROL MATERIAL HAS NOTBEEN ESTABLISHED WITH ANY OTHER ANTI-HCV ASSAYS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MZO Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus